About The Peter Moss Leukaemia MedTech Research
In 2018 Peter Moss, my grandfather, was diagnosed terminally ill with Acute Myeloid Leukaemia. One month before his prognisis, he was given the all clear in a routine blood test with no signs of Acute Myeloid Leukaemia. I was convinced that there must have been signs in the routine blood test that could have identified the disease.
I had previous experience with using Artificial Intelligence for breast cancer detection through the Breast Cancer AI project, and wanted to see if this experience could be used to help with the detection of Acute Myeloid Leukaemia.
I created the Peter Moss Acute Myeloid & Lymphoblastic Leukaemia AI Research Project, an open-source research project dedicated to creating free technologies focused on the detection of Acute Myeloid & Lymphoblastic Leukaemia. The long term goal of the research project was to work towards Artificial Intelligence that could one day be used for early detection of the Leukaemia, an issue that remains under research globally and unsolved.
Since the research project began, we have published 13 open-source and free projects focused on the detection of Acute Lymphoblastic Leukaemia using Artificial Intelligence.
The research project progressed very quickly over the following year. We demonstrated our technology and presented our mission at a number of events throughout Europe with Intel such as Embedded World 2019 in Germany, Codemotion Madrid 2019 and Intel Developer Affinity Day in Germany.
In 2019 we were awarded the Intel® DevMesh AI Spotlight Award for the Acute Lymphoblastic Leukaemia Detection System 2019. The project was one of 4 projects, and 1st from Europe, awarded the then new designation granted by Intel recognizing inspiring and breakthrough Artificial Intelligence projects in development from the Intel software community.
In August 2019, after battling Acute Myeloid Leukaemia for one day short of a year, Peter sadly passed away. This was a devastating time for the family, and made Adam determined to continue the research projects so that one day our technology and information could play a direct role in the lives of Leukaemia patients and their families.
In 2020 Asociación de Investigacion en Inteligencia Artificial Para la Leucemia Peter Moss, was created to allow our group of volunteers to continue our mission. The Association made great progress over the following year and a half: securing collaborations with Lancaster Intelligent, Robotic and Autonomous Systems Centre, Connecting Europe Facility, FIWARE, Barcelona Health Hub, and Catalan IoT Alliance; having success stories published by Connecting Europe Facility and FIWARE; being nominated for the Barcelona Health Hub Best Innovative Initiative Award, and being featured by Intel at Intel Innovation (IntelON) in the Tech for Good: Intel Innovation Keynote.
In November 2021, I returned to the United Kingdom and Peter Moss Leukaemia MedTech Research CIC, a Community Interest Company, was formed to continue the work we began in 2018.
Peter Moss Leukaemia MedTech Research CIC is a Community Interest Company, limited by guarantee and regulated by the C.I.C. Regulator.
In loving memory of Peter Edward Moss, 5th Aug 1939 - 24th Aug 2019, who bravely battled Acute Myeloid Leukaemia. A loving husband, father, grandfather and great grandfather.